Differential cytokine expression in EBV positive peripheral T cell lymphomas by Liang, RHS et al.
Title Differential cytokine expression in EBV positive peripheral T celllymphomas
Author(s) Ho, JWY; Liang, RHS; Srivastava, G
Citation Journal Of Clinical Pathology - Molecular Pathology, 1999, v. 52n. 5, p. 269-274
Issued Date 1999
URL http://hdl.handle.net/10722/53405
Rights Journal of Clinical Pathology. Copyright © B M J PublishingGroup.
DiVerential cytokine expression in EBV positive
peripheral T cell lymphomas
J W Y Ho, R H S Liang, G Srivastava
Abstract
Aim—To investigate whether specific cy-
tokines are secreted locally at the tumour
site in Epstein-Barr virus (EBV) positive
peripheral T cell lymphoma (PTCL).
Methods—An RNase protection assay sys-
tem was used to study the diVerential
expression of 21 cytokines in parallel in
eight cases of EBV positive non-nasal
PTCL, and compared with 11 EBV nega-
tive non-nasal PTCLs and three EBV
positive nasal natural killer (NK) cell lym-
phomas.
Results—Among the eight EBV positive
cases, interferon ã (IFN-ã), lymphotoxin â
(LTâ), interleukin 10 (IL-10), tumour
necrosis factor á (TNF-á), transforming
growth factor â1 (TGF-â1), and IL-1
receptor a (IL-Ra) were frequently detect-
able. IL-15, IL-6, IL-4, IL-1â, TNF-â, and
IL-9 were sporadically detectable. Of the
frequently detectable cytokines, IFN-ã
and LTâ were commonly detected in the
EBV negative cases. For cases with > 50%
EBV encoded small non-polyadenylated
RNA (EBER) positive cells, IL-10, TNF-á,
and TGF-â1 were detected in three of
three cases, and IL-1Ra in two of three
cases. For cases with < 20% EBER positive
cells, IL-10 was detected in three of five
cases, TNF-á in two of four cases, but
TGF-â1 and IL-1Ra were not detected.
Interestingly, IL-6 was detected in two of
three cases with > 50% EBER positive
cells, but only in one of five cases with
< 20% EBER positive cells. For compari-
son, in NK cell lymphomas, IL-10, TNF-á,
IL-1Ra, and IL-6 were all detectable, but
TGF-â1 was not detected at all. Immuno-
histochemical staining revealed IL-10 in
many cells; in contrast, EBV latent mem-
brane protein 1 (LMP1) was only found to
be positive in isolated cells.
Conclusions—Certain cytokines, such as
IL-10 and TNF-á, might be expressed
preferentially in EBV positive peripheral
T cell lymphomas. It is likely that such a
cytokine environment enhances EBV in-
fection and contributes towards tumori-
genesis.
(J Clin Pathol:Mol Pathol 1999;52:269–274)
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In primary nasal T/natural killer (NK) cell
lymphomas, Epstein-Barr virus (EBV) is asso-
ciated with 100% of cases,1 2 the virus exists as
a single clonal episome, and is found in almost
all tumour cells.2 In non-nasal peripheral T cell
lymphoma (PTCL), EBV is detected in only
52% of cases,3 the virus might be monoclonal
or biclonal, and is found only in a proportion of
atypical cells. EBV infection and cytokine
expression are closely associated in B cells,4
and we speculate that specific cytokines are
secreted locally in the tumour environment of
EBV positive PTCLs.
In vitro studies on EBV infection suggest
that viral survival in lymphoblastoid cells can
be maintained largely by cytokine mediated
autocrine loops.4 In vivo studies have shown
that various cytokine genes can be upregulated
in a number of EBV associated malignancies.5–8
Many cytokines are suspected to contribute
towards the histological characteristics and
clinical behaviour of tumours.9–14 Moreover,
large numbers and variable amounts of cy-
tokines are found in various malignant
lymphomas.10 14
From the literature, it is clear that the
expression of many cytokines is altered in
peripheral T cell lymphomas. To date, how-
ever, the diVerential expression of a panel of
cytokines in EBV positive peripheral T cell
lymphomas has not been reported. Therefore,
it is not clear whether EBV infection is associ-
ated with upregulation of cytokines in the
microenvironment of PTCLs. We have exam-
ined cytokine expression in EBV positive non-
nasal peripheral T cell lymphomas, compared
with EBV negative non-nasal PTCLs, as well as
with nasal NK cell lymphoma. The results
obtained should give an insight into the factors
influencing viral survival in the tumour envi-
ronment of peripheral T cell lymphomas.
Table 1 Peripheral T cell lymphoma (PTCL) and natural
killer cell lymphoma (NL)
PTCL
NL
EBV
positive
EBV
positive
EBV
negative
Frequently detectable cytokines
IFN-ã 8/8 10/11 3/3
LTâ 7/7 9/10 2/2
IL-10 6/8 5/11 3/3
TNF-á 5/7 5/10 2/2
TGF-â1 4/7 9/10 0/2
IL-1Ra 4/8 9/11 2/2
Sporadically detectable cytokines
IL-15 3/7 3/10 3/3
IL-6 3/8 5/10 3/3
IL-4 3/8 1/11 0/3
IL-1â 2/8 4/10 0/2
TNF-â 0/7 4/10 0/2
IL-9 0/7 2/10 0/3
Frequently detectable cytokines are detected in 50% or more
cases of Epstein-Barr virus (EBV) positive PTCLs.
Sporadically detectable cytokines are detected in less than 50%
of cases of EBV positive PTCLs.
IFN-ã, interferon ã; IL, interleukin; IL-1Ra, IL-1 receptor a;
LTâ, lymphotoxin â; TGF-â1, transforming growth factor â1;
TNF, tumour necrosis factor.
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Materials and methods
The RNase protection assay (RPA) requires a
large amount of snap frozen material from each
case, but the biopsy samples were often very
small, particularly those from the nasal cases.
SuYcient frozen biopsy samples were available
from eight cases of EBV positive non-nasal
PTCL, 11 cases of EBV negative non-nasal
PTCL, and three cases of EBV positive
primary nasal NK cell lympoma. Essentially,
the19cases includedfivecasesofangioimmuno-
blastic T cell lymphoma (AIL), two of Ki-1
large cell anaplastic T cell lymphoma (LCAL),
two of lymphoepithelioid lymphoma (LEL),
one of mycosis fungoides (MF), eight of
pleomorphic medium size and large T cell
lymphoma (PL), and one of T zone lymphoma
(TZ). All biopsies were from the lymph node
except for one PL case from the intestine and
two cases from skin (oneMF and one PL). The
eight EBV positive cases included four cases of
AIL, two of PL, one of LEL, and one of MF.
The 11 EBV negative cases consisted of one
case of AIL, six of PL, two of LCAL, one of
LEL, and one of TZ. All cases were selected
from the files in the department of pathology,
Queen Mary Hospital, Hong Kong. They were
all diagnosed according to the updated Kiel
classification.15 16 All patients were Chinese and
had no apparent immunodeficiency.
The phenotypic profile for each case was
established at the time of diagnosis.3 17 The
tumour cells in all cases expressed at least one
T cell or NK cell antigen and no B cell
antigens. Genotyping18 to confirm T cell
lineage was performed for the eight cases of
EBV positive PTCL.3 Immunostaining for
EBV latent membrane protein 1 (LMP1) and
EBV nuclear antigen 2 (EBNA2) using mono-
clonal antibodies CS.1-4 and PE2, respec-
tively, was performed on 6 µm frozen sections,
as described previously.19 Immunostaining for
interleukin 10 (IL-10) using goat polyclonal
antibody (R&D, Minneapolis, MN, USA) was
performed on 6 µm frozen sections using the
LSAB+ kit (Dako, Glostrup, Denmark), ac-
cording to the manufacture’s instructions.
In situ hybridisation (ISH) for EBV encoded
small non-polyadenylated RNA (EBER) was
performed using the EBV–ISH kit from Dako,
as reported previously.3
Total RNA was extracted from frozen tissues
of each case and the control cell lines by the
acid guanidinum thiocyanate/phenol/
chloroform method.20 For the detection of
LMP1 and EBNA2 mRNA expression, reverse
transcription–polymerase chain reaction (RT–
PCR) followed by Southern blot hybridisation
Table 2 Summary of mRNA expression of EBER by ISH; LMP1 and EBNA2 by
RT–PCR; and the detectable cytokines by RNase protection assay in Epstein-Barr virus
(EBV) positive peripheral T cell lymphomas (PTCLs) of diVerent subtypes
1 2 3 4 5 6 7 8
Subtype AIL PL MF AIL AIL AIL LEL PL
EBER >50%# >50% >50% <20%* <20% <20% <20% <20%
LMP1 + + + + + + + +
EBNA2 − − − + − − − +
IFN-ã + + + + + + + +
LTâ + + + + + + + ND
IL-10 + + + + + + − −
TNF-á + + + − − + + ND
TGF-â1 + + + − − − + ND
IL-1Ra − + + + − − − +
IL-15 − − − + + + ND −
IL-6 + + − + − − − −
IL-4 − − − − + + + −
IL-1â − + − − − − − +
#EBER was positive in >50% of the atypical cells; *EBER was positive in <20% of the atypical
cells.
AIL, angioimmunoblastic T cell lymphoma; EBER, EBV encoded small non-polyadenylated
RNAs; EBNA2, EBV nuclear antigen 2; IFN-ã, interferon ã; IL, interleukin; IL-1Ra, IL-1 recep-
tor 1; ISH, in situ hybridisation; LEL, lymphoepithelioid lymphoma; LTâ, lymphotoxin â; MF,
mycosis fungoides; ND, not determined; PL, pleomorphic medium size and large T cell
lymphoma; RT–PCR, reverse transcription–polymerase chain reaction; TGF-â1, transforming
growth factor â1; TNF-á, tumour necrosis factor á.
Figure 1 Detection of Epstein-Barr virus (EBV) encoded small non-polyadenylated RNA (EBER) 1 and 2 by in situ
hybridisation (ISH) using a fluorescein isothiocyanate (FITC) labelled probe. (A) EBER was positive in ∼ 50% of
atypical cells including blast like cells. (B) EBER was only positive in a subpopulation (up to 20%) of atypical cells
including blast like cells. (C) LMP1 protein was positive in isolated cells. (D) Interleukin 10 (IL-10) protein was positive
in many cells showing cytoplasmic staining.
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was carried out as described previously.19 The
primers and probes used have also been
described previously.19
Three template sets were used for RPA
(Pharmingen, San Diego, USA). Each set con-
tains DNA templates that can be used for the
T7 polymerase directed synthesis of 32P la-
belled antisense RNA probes that can in turn
hybridise with target human mRNA encoding
IL-5, IL-4, IL-10, IL-14, IL-15, IL-9, IL-2,
IL-13, and interferon ã (IFN-ã) (hCK-1);
IL-12p35, IL-12p40, IL-10, IL-1á, IL-1â, IL-1
receptor a (IL-1Ra), IL-6, and IFN-ã (hCK-
2); TNF-â, lymphotoxin â (LTâ), tumour
necrosis factor á (TNF-á), IFN-ã, IFN-â,
transforming growth factor â3 (TGF-â3),
TGF-â2, and TGF-â1 (hCK-3). These assays
were carried out essentially according to the
manufacturer’s instructions.
Results
Table 1 summarises the expression of the
cytokines. Table 2 summarises the histological
subtypes, expression of EBV, and cytokine gene
transcripts for the eight EBV positive cases.
Among the eight EBV positive cases, three
cases showed > 50% EBER positive cells (fig
Figure 2 Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA2) and EBV latent
membrane protein 1 (LMP1) mRNA expression analysis for the eight EBV positive
peripheral T cell lymphomas (PTCLs) by reverse transcription–polymerase chain reaction
(RT–PCR) followed by Southern blot hybridisation.Whereas EBNA2 mRNA was
detected in cases 3 and 8 only, LMP1 mRNA was detected in all eight cases. The B95.8 cell
line was used as a positive control.
DNA
EBNA2
209 bp
DNA
LMP1
104 bp
B95.8 1 2 3 4 5 6 7 8
Figure 3 Multiprobe RNase protection assay for the detection of cytokines using hCK-1, hCK-2, and hCK-3 probe sets.
Lane 1 shows the unprotected probe sets. Lane 2 shows the corresponding RNase protected probes after hybridisation with
the total RNA (2 µg; provided by PharMingen) as positive control. Lane 3 shows the corresponding RNase protected probes
after hybridisation with total RNA (5 µg) from a case of Epstein-Barr virus (EBV) positive angioimmunoblastic T cell
lymphoma (AIL). The negative control using yeast tRNA (2 µg) is not shown.Note that each probe band (lane 1)
migrates more slowly than its protected bands (lanes 2 and 3); this is the result of flanking sequences in the probe that are
not protected by mRNA.Because of the diVerences in the expression of diVerent cytokines, the exposure time for each lane
varied, resulting also in variations in the intensity of the housekeeping gene L32. The undigested probe sets were also loaded
(typically 1000–2000 counts/minute/lane) as markers. IFN, interferon; IL, interleukin; IL-1Ra, IL-1 receptor; LTâ,
lymphotoxin â; TGF, transforming growth factor; TNF; tumour necrosis factor.
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1A) and five cases showed < 20% EBER posi-
tive cells (fig 1B). The three nasal cases showed
EBER positive cells in more than 70% of the
atypical cells. All eight cases showed LMP1
mRNA expresssion, and two cases showed
EBNA2 mRNA expression (fig 2). However,
using immunohistochemical staining, LMP1
was detected only in isolated cells (fig 1C), and
EBNA2 was not detected at all.
Figure 3 illustrates the results obtained from
the RPA system. Each set of RPA analysis
requires a minimum of 5 µg of total RNA, so
that each analysis could only be repeated once
because of the limited amounts of tissue avail-
able for our study. The x ray film was given
maximum exposure to avoid underdetection.
Our aim was to identify the presence or
absence of the cytokines in the tumour
environment. Overall, 12 of 21 cytokines
showed detectable levels of expression. Nine of
21 cytokines, namely IL-5, IL-14, IL-2,
IL-12p35, IL-12p40, IL-1á, IFN-â, TGF-â3,
and TGF-â2 were not detected by RPA; either
their expression level was below the detection
limit or they were not expressed.
NON-NASAL PTCL
Frequently detectable cytokines
As shown in Tables 1 and 2, irrespective of the
presence of EBV, IFN-ã and LTâ were detect-
able in almost all cases. In cases with > 50%
EBER positive cells, IL-10, TNF-á, and
TGF-â1 were uniformly detectable (three of
three cases), and IL-1Ra was frequently
detectable (two of three cases). In cases with
< 20% EBER positive cells, only IL-10 was
preferentially detectable (three of five cases).
Overall, IL-10 and TNF-á were marginally
more frequently detected in EBV positive cases
compared with EBV negative cases. At the cel-
lular level, the IL-10 protein was detected by
immunohistochemistry in the cytoplasm of
many cells (fig 1D). Table 3 compares the pro-
duction of the IL-10 protein with the EBV
proteins, namely LMP1 and EBNA2.
Sporadically detectable cytokines
These cytokines are listed in table 1. However,
in cases with > 50% EBER positive cells, IL-6
was frequently detectable (two of three cases).
In contrast, in cases with < 20% EBER positive
cells, IL-6 was rarely detectable (table 2). In
EBV negative cases, most of these cytokines
were detected sporadically (table 1).
NK CELL LYMPHOMA
IFN-ã, LTâ, IL-10, TNF-á, IL-1Ra, IL-15,
and IL-6 were detectable in every tested case of
EBV positive NK cell lymphoma. In PTCL
cases with > 50% EBER positive cells,
TGF-â1 was not detected at all, whereas IL-6
and IL-1Ra were detected in all cases.
Discussion
The study of cytokine expression by means of
RPA indicated that cytokines can be diVerenti-
ated into two sets: those cytokines that are
associated directly with the presence of EBV
and those that are not.
Irrespective of EBV infection, IFN-ã and
LTâ were commonly detectable in all cases.
Together with most of the sporadically detect-
able cytokines, namely IL-15, IL-4, IL-1â,
TNF-â, and IL-9 (table 1), these cytokines do
not correlate specifically with EBV infection.
Instead, the expression of many of these
cytokines correlated well with the tumour
entities.12 21–23
TGF-â1 was detectable in all three cases
with > 50% EBER positive cells. This potent
immunosuppressive agent has been detected
before in the tumour cells of PTCLs,24 but no
reference was made to the presence of EBV. Its
absence in other EBV positive PTCLs and all
three cases of EBV positive NK cell lymphoma
suggest that this cytokine might not play a
direct and primary role in EBV infection.
However, it might have a cooperative role in
PTCLs that harbour high numbers of EBV.25 26
Similarly, IL-1Ra and IL-6 were detectable in
two of three cases with > 50% EBER positive
cells. Unlike TGF-â1, they were detectable in
every cases of EBV positive NK cell lymphoma
tested. Such a correlation suggests that these
two cytokines are associated only indirectly
with both T and NK cell tumours that harbour
high numbers of EBV.27
Others have reported IL-10 expression in
PTCLs to be subtype specific rather than asso-
ciated with EBV28; our result did not show the
same trend. Among the six frequently detect-
able cytokines, IL-10 and TNF-á showed mar-
ginal preferential expression in the eight EBV
positive PTCLs. They were also detected in all
cases of EBV positive NK cell lymphoma.
These two cytokines did not appear to be
lymphoma subtype specific.
IL-10 is a pleiotropic cytokine. It is a potent
immunosuppressor of cytotoxic T cells and a
costimulator of B cell growth. Presented to NK
cells, IL-10 is found to mediate IL-2 induced
NK production of IFN-ã.29 IL-10 has been
associated with many EBV associated malig-
nancies, such as Hodgkin’s disease and
Burkitt’s lymphoma, in which it is thought to
mediate immunosuppression in the
microenvironment.7 8
EBV gene transcript studies of the eight
cases revealed that only isolated cells were
LMP1 positive, irrespective of the percentage
of EBER infected cells, indicating mixed
latency I and II EBV positive cells. The detec-
tion of EBNA2 at the mRNA level, but not at
the protein level, suggests that there might be
rare latency III cells in the tumour cell popula-
tion of the two cases. Therefore, the latency
pattern appears to be similar to that of EBV
positive NK cell lymphoma, the EBV gene
expression pattern of which has been studied
Table 3 Expression of LMP1,EBNA2, and IL-10 (as measured by immunohistochemistry)
in Epstein-Barr virus (EBV) positive peripheral T cell lymphomas
1 2 3 4 5 6 7 8
Subtype AIL PL MF AIL AIL AIL LEL PL
LMP1 + + + + + + − +
EBNA2 − − − − − − − −
IL-10 + + + + − + − −
AIL, angioimmunoblastic T cell lymphoma; EBNA2, EBV nuclear antigen 2; IL-10, interleukin
10; LEL, lymphoepithelioid lymphoma; MF, mycosis fungoides; PL, pleomorphic medium size
and large T cell lymphoma.
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previously.19 In contrast to the isolated detec-
tion of LMP1 positive cells, immunostaining
revealed, at the cellular level, that many cells
stained positive for IL-10, irrespective of the
percentage of EBER positive cells. The per-
centage of IL-10 positive cells did not appear to
correlate with the percentage of EBER positive
cells. In vitro studies on B cell lines suggest that
IL-10 expression might be transactivated by
LMP1,30 but this has not been studied in T cell
lines or T cell tumours; therefore, the eVect of
EBV proteins and IL-10 on each other in T
cells is not clear. We suspect that IL-10 was
already present in the tumour environment
upon viral infection, but further studies are
needed to clarify whether or not EBV had a
sustaining or enhancing eVect on IL-10
expression. Moreover, our results indicate that
there is no correlation between IL-10 and
EBNA2 expression. However, this also needs
to be clarified further in future in vitro studies.
Comparing the two immunosuppressive
agents, TGF-â1 was detected more frequently
in EBV negative cases, whereas IL-10 was
detected more often in EBV positive cases.
Interestingly, in cases with > 50% EBER posi-
tive cells, both IL-10 and TGF-â1 were
expressed. In contrast, in the highly EBV asso-
ciated NK cell lymphoma, IL-10 was detect-
able, but TGF-â1 was not (table 1). Thus,
EBV infection correlates with IL-10 expression
both in non-nasal PTCL and NK cell
lymphoma, and local immunosuppression in
EBV positive cases might be the result of IL-10
rather than TGF-â1 expression. The coexpres-
sion of TGF-â1 and IL-10 is unique in cases
with > 50% EBER positive cells, so their eVect
on immunosuppression in those cases will
require further study.
TNF-á is also a pleiotropic cytokine, and it
can be produced by B and T cells, as well as
NK cells. EBV infection of B cells promotes its
expression,8 and it has been detected in EBV
positive B immunoblasts in AILD cases.31
Recent studies have shown that EBV positive T
cells also upregulate TNF-á expression.6 Fur-
thermore, EBV selectively upregulated TNF-á
expression over IFN-ã and IL-1á.6 TNF-á and
TNF-â are known to be functionally redun-
dant cytokines in many aspects. Interestingly,
our study shows that in the EBV negative cases,
the frequency of detection of TNF-á and
TNF-â was similar. In EBV positive cases,
however, there was a preferential upregulation
of TNF-á and downregulation of TNF-â (table
1). In comparison, TNF-á is also detected
selectively in EBV positive NK cell lymphoma.
This is interesting because in normal NK cells,
upregulation of TNF-á induced apoptosis.32
In summary, among the 21 cytokines
studied, we noted a trend for the preferential
expression of IL-10 and TNF-á in EBV
positive non-nasal PTCL. This finding corre-
lates strongly with a similar survey on EBV
immortalized B cell lines.4 Thus, in EBV posi-
tive non-nasal PTCL, the strongest candidates
associated directly with EBV infection are
IL-10 and TNF-á. Furthermore, at the cellular
level, as shown by protein staining, the
detection of more IL-10 positive cells com-
pared with EBER and LMP1 suggests that
such cytokine environments might enhance
EBV infection and contribute towards tumori-
genesis.
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